Prolongation of survival of nude mice bearing human colon cancer. Treatment with yttrium 90-labeled anti-carcinoembryonic antigen antibody.
Nude mice bearing diffuse intraperitoneal carcinomatosis of the human colon cancer cell line LS174T were treated with an anti-carcinoembryonic antigen monoclonal antibody (MAB) that was labeled with yttrium 90 (90Y-ZCE025). Control animals were either untreated or treated with nonspecific 90Y-MAB (90Y-96.5c). The median survival (MS) for untreated animals was 26 days. The MS for specific and nonspecific therapy that consisted of 120 microCi of 90Y-MAB was 69 and 34 days, respectively. No significant improvement in the MS was observed with a second 120-microCi administration of 90Y-MAB given two weeks later. A decreased MS was observed with 80 microCi of 90Y-MAB given every four days for three cycles. In each category, specific therapy had a significant advantage over nonspecific therapy in increased effectiveness and decreased toxicity. The 90Y-ZCE025 therapy gave an increased life span of almost 200%. The therapeutic effects with different dosing regimens have important implications for treatment planning.
Hyams
D M
DM
Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, Calif 91010.
Esteban
J M
JM
Beatty
B G
BG
Wanek
P M
PM
Beatty
J D
JD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000032:analysis / Q000276:immunology*; D002277:Carcinoma / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D002460:Cell Line; D003110:Colonic Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D015021:Yttrium Radioisotopes